Abstract: Paralysis occurring in amyotrophic lateral sclerosis (ALS) results from denervation of skeletal muscle as a consequence of motor neuron degeneration. Interactions between motor neurons and glia contribute to motor neuron loss, but the spatiotemporal ordering of molecular events that drive these processes in intact spinal tissue remains poorly understood. Here, we use spatial transcriptomics to obtain gene expression measurements of mouse spinal cords over the 5 course of disease, as well as of postmortem tissue from ALS patients, to characterize the underlying molecular mechanisms in ALS. We identify novel pathway dynamics, regional differences between microglia and astrocyte populations at early time-points, and discern perturbations in several transcriptional pathways shared between murine models of ALS and human postmortem spinal cords.
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One Sentence Summary: Analysis of the ALS spinal cord using Spatial Transcriptomics reveals spatiotemporal dynamics of disease driven gene regulation.
Main Text:
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which symptoms typically manifest at first in distal muscles of a single limb. Symptoms then spread throughout the body, ultimately leading to total paralysis. Loss of locomotor control is the 15 result of denervation of skeletal muscles and motor neuron death. However, the events that initiate disease pathology, and the mechanisms through which pathology spreads remain poorly understood (1) (2) (3) (4) . Mounting evidence indicates that dysfunction in signaling between motor neurons and glia is a key component of the disease (1, 5, 6) . Inherent limitations of widely available gene expression profiling technologies, such as low throughput or lack of spatial 20 resolution have thus far frustrated efforts to understand how such dysfunction participates in the onset and spread of ALS pathology in the spinal cord. Given the stereotyped cellular organization of the spinal cord and the known importance of intercellular communication in ALS 3 progression, we reasoned that a spatially resolved view of disease driven gene expression changes would be needed to order these events, reveal the relevant sub-populations of cells involved in each stage in disease progression, and characterize the underlying molecular mechanisms that trigger and maintain the disease phenotype.
Spatial Transcriptomics (ST) generates quantitative transcriptome-wide RNA sequencing 5 (RNAseq) data via capture of polyadenylated RNA on arrays of spatially barcoded DNA capture probes (7) (8) (9) . We applied ST to spatially profile gene expression in lumbar spinal cord tissue sections (L3-L5) from SOD1-G93A (ALS) and SOD1-WT (control) mice at pre-symptomatic, onset, symptomatic, and end-stage time points (Table S1) . We then applied ST to profile gene expression in postmortem lumbar and cervical spinal cord tissue sections from either lumbar or 10 bulbar onset sporadic ALS patients resulting in over 76 thousand spatial gene expression measurements (SGEMs), mapping to ~1200 spinal cord tissue sections of 67 mice, and over 60 thousand SGEMs mapping to 80 postmortem spinal cord tissue sections from seven patients (Table S1 ). An interactive data exploration portal for our ST analysis is available at http://alsst.nygenome.org/. 15 We annotated each SGEM with an anatomical annotation region (AAR) tag, and used these tags to conduct differential expression analysis and to register the data to a common coordinate system (Figs. S1,S2; Table S1 ). To estimate gene expression levels accurately and detect significant regional, anatomical, and cell type changes within and between conditions, we formulated a novel hierarchical generative probabilistic model (Data 1). Our model corrects for 20 missing data due to undersampling and bias, which has been a common issue in spatial and single cell RNAseq (scRNAseq) studies. As a result, we reliably quantitated the spatial distribution of 11,138 genes in mouse and 9,624 genes in human spinal cord sections. 4 Furthermore, principal component analysis of the complete mouse SGEM dataset reveals that the majority of the variance is explained by spatial location, disease state, and genotype (Fig. S3) , and not by batch effects.
Our analysis recapitulates the specific regional and temporal expression patterns for genes with previously described regional expression profiles (Mbp, Ebf1, and Slc5a7) (10) (11) (12) and roles in 5 ALS progression (Aif1, Gfap) (13) . Immunofluorescence (IF) imaging of the protein products of these genes demonstrates spatial concordance with our analysis ( Fig. 1 ; Tables S2,S3 ). Furthermore, our observations, shown for example by Fcrls, Aif1, Gfap and Aldh1l1, suggest that microglial dysfunction occurs well before symptom onset, precedes astroglial dysfunction in ALS, and that this early microglial dysfunction is proximal to motor neurons (Table S3 ; Fig. S4 ). 10 To further explore the spatiotemporal dynamics of microglial activation, we focused on a mechanism involving TREM2 reported in several neurodegenerative disease models (6, 14, 15) .
TREM2 and TYROBP form a receptor complex that can trigger phagocytosis or modulate cytokine signaling when engaged by membrane lipids, or lipoprotein complexes (15, 16) . This mechanism also involves Apoe, Lpl, B2m, and Cx3cr1, and is activated by microglial 15 phagocytosis of apoptotic neurons. Lpl is expressed by microglia of the CNS, and aids in the uptake of myelin derived lipids, a process that can modulate microglial activation (17) . Spatial gene expression analysis suggests a spatiotemporal ordering of this TREM2-mediated mechanism in ALS. We observe that Tyrobp is upregulated pre-symptomatically and before Table S3 ; Fig. S4 ). These latter genes become widely upregulated in spinal cords of symptomatic mice (Table S3) . Apoe expression is driven by Trem2 signalling, 5 and is itself a ligand for Trem2, and therefore, Apoe and Trem2 expression can act in an autoregulatory loop that can trigger and maintain a phagocytic microglial phenotype (18) .
Collectively, our spatial analysis suggests that TREM2/TYROBP mediated signaling is an early step in disease relevant changes in microglial gene expression. Further, the spatiotemporal ordering of gene expression changes that we observe adds to what can be learned using single 5 cell RNA sequencing of sorted microglia (6, 14) , demonstrating the value of spatially-resolved high dimensional analyses. dysfunction in autophagy to gliosis and motor neuron loss in ALS, we applied our methods to these mice (Atg7 cKO). As expected, we observe that expression of Gfap and Aif1, and activity of the TREM2 microglial activation axis, are greatly reduced when autophagy is ablated in motor neurons, particularly in AARs distal to motor neuron somata (Table S3) .
To better understand disease relevant changes in gene regulation and interactions between cell 20 types, we carried out an unbiased co-expression analysis of our mouse ST data. We identified 31 major co-expression modules (Methods; Fig. 3A ; Table S4 ) of diverse spatiotemporal and pathway activities, a subset of which are affected in Atg7 cKO ( Fig. 3B ; Figs. S6,S7A; Table   6 S5). Examining these modules in the context of published scRNAseq data (23) reveals that many of the modules are comprised of genes preferentially expressed in specific cell types (Fig. S7B ).
We further grouped the genes of each module based on their cell-type specific expression pattern, resulting in submodules (Methods; Fig. 3C ; Tables S6,S7 This approach also allows us to identify coordinated activities across cell types that reflect major aspects of disease, and to highlight expression programs within distinct cell types associated with these processes (Fig. S7B) . In one such example, a microglial expression program containing analysis of these submodules shows that they are both enriched for lysosomal factors (Fig. 3D) (Fig. S8D) . Several findings from our mouse study are recapitulated in postmortem spinal cords of sporadic ALS patients. We applied our ST workflow to cervical and lumbar tissue from four patients who 20 presented clinically with bulbar symptom onset, and three patients who presented with lower limb symptom onset. Data from these human samples exhibits expected regional expression patterns, resembling those from the mouse dataset (Fig. S9) . Consistent with previous studies 9 (29) , human spatial data shows variability in gene expression in the anterior horn related to distance from the site of symptom onset (Table S10 ). For instance, acetylcholinesterase (ACHE), the activity of which has been linked to neuromuscular defects in ALS (16, 19) , shows reduced expression at locations proximal to spinal segments innervating the site of symptom onset (Fig.   4A,B) . As with the mouse spatial data, we conducted an unbiased co-expression analysis on the 5 human spatial data, resulting in 28 human expression modules ( Fig. S10A,B ; Table S8 ). The spatial mapping patterns for these human expression modules demonstrate AAR characteristic patterns, some of which vary along the rostrocaudal axis (Fig. 4C) , or differ between white matter and grey matter (Fig. S10B) , or with proximity to site of symptom onset (Fig. S10B ). For example, human expression module 3 is attenuated across spinal cord sections at sites proximal 10 to symptom onset (Fig. 4C) . Furthermore, this attenuation is most pronounced in the posterior white matter and anterior horns. KEGG analysis shows that human module 3 is enriched for several pathways, including sphingolipid, retrograde endocannabinoid, and WNT signaling (Table S9 ). This finding, along with several human and mouse submodules that display disease relevant dynamics and that are enriched for sphingolipid signaling pathways, underscores the 
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Figs S1 -S10 Average spatiotemporal expression dynamics of the genes of the human co-expression modules 3, 25, and 27 are visualized.
